ATE156488T1 - Triesters von phosphorothioaten oligonukleotiden und verfahren zur herstellung - Google Patents

Triesters von phosphorothioaten oligonukleotiden und verfahren zur herstellung

Info

Publication number
ATE156488T1
ATE156488T1 AT94916273T AT94916273T ATE156488T1 AT E156488 T1 ATE156488 T1 AT E156488T1 AT 94916273 T AT94916273 T AT 94916273T AT 94916273 T AT94916273 T AT 94916273T AT E156488 T1 ATE156488 T1 AT E156488T1
Authority
AT
Austria
Prior art keywords
pct
triesters
production
sec
date
Prior art date
Application number
AT94916273T
Other languages
English (en)
Inventor
Jean-Louis Imbach
Bernard Rayner
Original Assignee
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient filed Critical Centre Nat Rech Scient
Application granted granted Critical
Publication of ATE156488T1 publication Critical patent/ATE156488T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
AT94916273T 1993-05-12 1994-05-11 Triesters von phosphorothioaten oligonukleotiden und verfahren zur herstellung ATE156488T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9305706A FR2705099B1 (fr) 1993-05-12 1993-05-12 Oligonucléotides phosphorothioates triesters et procédé de préparation.

Publications (1)

Publication Number Publication Date
ATE156488T1 true ATE156488T1 (de) 1997-08-15

Family

ID=9447046

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94916273T ATE156488T1 (de) 1993-05-12 1994-05-11 Triesters von phosphorothioaten oligonukleotiden und verfahren zur herstellung

Country Status (7)

Country Link
US (1) US5770713A (de)
EP (1) EP0698034B1 (de)
AT (1) ATE156488T1 (de)
CA (1) CA2162684A1 (de)
DE (1) DE69404835T2 (de)
FR (1) FR2705099B1 (de)
WO (1) WO1994026764A1 (de)

Families Citing this family (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6153595A (en) * 1990-08-16 2000-11-28 Isis Pharmaceuticals Inc. Composition and method for treatment of CMV infections
US5849905A (en) * 1994-11-23 1998-12-15 Centre National De La Recherche Scientifique Biologically active phosphotriester-type nucleosides and methods for preparing same
US6784290B1 (en) 1992-10-05 2004-08-31 Isis Pharmaceuticals, Inc. Antisense oligonucleotide inhibition of ras
NZ256974A (en) * 1992-10-05 1997-12-19 Isis Pharmaceuticals Inc Oligonucleotides and compositions thereof for modulating expression of the human ras gene
US5872242A (en) * 1992-10-05 1999-02-16 Isis Pharmaceuticals, Inc. Antisense oligonucleotide inhibition of ras
US20020120130A1 (en) * 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
WO1995007086A1 (en) 1993-09-10 1995-03-16 Emory University Nucleosides with anti-hepatitis b virus activity
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US6391636B1 (en) 1994-05-31 2002-05-21 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US5981731A (en) * 1994-05-31 1999-11-09 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of B-raf gene expression
AU3675195A (en) * 1994-09-07 1996-03-27 Hybridon, Inc. Oligonucleotide prodrugs
EP0831852B1 (de) 1995-06-07 2006-11-29 Emory University Nucleoside mit anti-hepatitis b virus wirksamkeit
US9096636B2 (en) 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
WO2005121370A2 (en) * 2004-06-03 2005-12-22 Isis Pharmaceuticals, Inc. Oligomeric compounds that facilitate risc loading
US7812149B2 (en) 1996-06-06 2010-10-12 Isis Pharmaceuticals, Inc. 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
WO1998007734A1 (en) * 1996-08-21 1998-02-26 Hybridon, Inc. Oligonucleotide prodrugs
US6716625B1 (en) 1997-04-16 2004-04-06 Claude Selitrennikoff Histidine kinases of Aspergillus and other fungal species, related compositions, and methods of use
US6528271B1 (en) 1997-06-05 2003-03-04 Duke University Inhibition of βarrestin mediated effects prolongs and potentiates opioid receptor-mediated analgesia
US6383808B1 (en) 2000-09-11 2002-05-07 Isis Pharmaceuticals, Inc. Antisense inhibition of clusterin expression
US6531590B1 (en) * 1998-04-24 2003-03-11 Isis Pharmaceuticals, Inc. Processes for the synthesis of oligonucleotide compounds
WO1999064434A1 (en) * 1998-06-11 1999-12-16 Isis Pharmaceuticals, Inc. Synthetic methods and intermediates for triester oligonucleotides
US5962672A (en) * 1998-09-18 1999-10-05 Isis Pharmaceuticals Inc. Antisense modulation of RhoB expression
US5962673A (en) * 1998-11-20 1999-10-05 Isis Pharmaceuticals Inc. Antisense modulation of inhibitor-kappa B kinase-alpha expression
US5959097A (en) * 1998-11-20 1999-09-28 Isis Pharmaceuticals, Inc. Antisense modulation of MEK2 expression
US5977341A (en) * 1998-11-20 1999-11-02 Isis Pharmaceuticals Inc. Antisense modulation of inhibitor-kappa B kinase-beta expression
US6492111B1 (en) * 1998-11-25 2002-12-10 Isis Pharmaceuticals, Inc. In situ binary synthesis of biologically effective molecules
US5981732A (en) * 1998-12-04 1999-11-09 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-13 expression
US20040082774A1 (en) * 1999-03-16 2004-04-29 Guzaev Andrei P. Novel phosphate and thiophosphate protecting groups
US6121437A (en) * 1999-03-16 2000-09-19 Isis Pharmaceuticals, Inc. Phosphate and thiophosphate protecting groups
US7098192B2 (en) 1999-04-08 2006-08-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of STAT3 expression
US6046321A (en) * 1999-04-09 2000-04-04 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-i1 expression
US20020055479A1 (en) 2000-01-18 2002-05-09 Cowsert Lex M. Antisense modulation of PTP1B expression
US6261840B1 (en) 2000-01-18 2001-07-17 Isis Pharmaceuticals, Inc. Antisense modulation of PTP1B expression
AU2001262108A1 (en) * 2000-03-17 2001-09-24 Unilever Plc Non-physiologic dna fragments for tanning skin
US7279324B2 (en) 2001-01-23 2007-10-09 Duke University Nucleic acid encoding G-protein coupled receptor with modified DRY motif
CA2790034A1 (en) 2001-06-21 2003-01-03 Isis Pharmaceuticals, Inc. Antisense modulation of superoxide dismutase 1, soluble expression
US6964950B2 (en) 2001-07-25 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of C-reactive protein expression
US20030096772A1 (en) 2001-07-30 2003-05-22 Crooke Rosanne M. Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US7227014B2 (en) 2001-08-07 2007-06-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein (a) expression
AU2002334895B2 (en) 2001-10-09 2006-10-19 Isis Pharmaceuticals, Inc. Antisense modulation of insulin-like growth factor binding protein 5 expression
US6750019B2 (en) 2001-10-09 2004-06-15 Isis Pharmaceuticals, Inc. Antisense modulation of insulin-like growth factor binding protein 5 expression
US6965025B2 (en) 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression
AU2003267785C1 (en) 2002-09-13 2009-12-24 Replicor, Inc. Non-sequence complementary antiviral oligonucleotides
US20050196382A1 (en) * 2002-09-13 2005-09-08 Replicor, Inc. Antiviral oligonucleotides targeting viral families
EP1549767A4 (de) 2002-09-26 2006-06-07 Amgen Inc Modulation der expression von forkhead-box o1a
EP1560839A4 (de) 2002-11-05 2008-04-23 Isis Pharmaceuticals Inc Chimäre oligomere verbindungen und derenverwendung in der genmodulation
AU2003287502B2 (en) 2002-11-05 2010-12-09 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
EP2336319A1 (de) 2002-11-13 2011-06-22 Genzyme Corporation Antisense-Modulation von Apolipoprotein-B-Expression
CA2505801A1 (en) 2002-11-13 2004-05-27 Rosanne Crooke Antisense modulation of apolipoprotein b expression
US7144999B2 (en) 2002-11-23 2006-12-05 Isis Pharmaceuticals, Inc. Modulation of hypoxia-inducible factor 1 alpha expression
WO2004065579A2 (en) * 2003-01-16 2004-08-05 Isis Pharmaceuticals, Inc. Modified oligonucleotides for use in gene modulation
WO2004072284A1 (en) 2003-02-11 2004-08-26 Antisense Therapeutics Ltd Modulation of insulin like growth factor i receptor expression
US7803781B2 (en) 2003-02-28 2010-09-28 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
US20040185559A1 (en) 2003-03-21 2004-09-23 Isis Pharmaceuticals Inc. Modulation of diacylglycerol acyltransferase 1 expression
US20040198640A1 (en) * 2003-04-02 2004-10-07 Dharmacon, Inc. Stabilized polynucleotides for use in RNA interference
US7598227B2 (en) 2003-04-16 2009-10-06 Isis Pharmaceuticals Inc. Modulation of apolipoprotein C-III expression
CN1984921B (zh) 2003-06-03 2010-06-16 Isis药物公司 存活蛋白表达的调节
CA2533701A1 (en) 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
US7825235B2 (en) 2003-08-18 2010-11-02 Isis Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 2 expression
US20070123480A1 (en) * 2003-09-11 2007-05-31 Replicor Inc. Oligonucleotides targeting prion diseases
JP5379347B2 (ja) * 2003-09-18 2013-12-25 アイシス ファーマシューティカルズ， インコーポレーテッド ４’−チオヌクレオシドおよびオリゴマー化合物
EP2256200A3 (de) 2003-09-18 2012-07-18 Isis Pharmaceuticals, Inc. Modulation der eIF4E Expression
JP2007507430A (ja) 2003-10-10 2007-03-29 メディテック リサーチ リミテッド 疾患の治療におけるヒアルロナン合成および分解の調節法
US20070269889A1 (en) * 2004-02-06 2007-11-22 Dharmacon, Inc. Stabilized siRNAs as transfection controls and silencing reagents
US8569474B2 (en) 2004-03-09 2013-10-29 Isis Pharmaceuticals, Inc. Double stranded constructs comprising one or more short strands hybridized to a longer strand
US8790919B2 (en) 2004-03-15 2014-07-29 Isis Pharmaceuticals, Inc. Compositions and methods for optimizing cleavage of RNA by RNase H
KR101147147B1 (ko) * 2004-04-01 2012-05-25 머크 샤프 앤드 돔 코포레이션 Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
US8394947B2 (en) 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
EP2409713B1 (de) 2004-08-10 2015-07-22 Genzyme Corporation Oligonukleotiden zur Verwendung in der Modulation der Lipoprotein- und Cholesterinspiegel beim Menschen
US7884086B2 (en) 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
ES2392449T3 (es) 2004-10-20 2012-12-10 Antisense Therapeutics Ltd Modulación antisentido de la expresión de la integrina alfa-4
US7923206B2 (en) * 2004-11-22 2011-04-12 Dharmacon, Inc. Method of determining a cellular response to a biological agent
US7935811B2 (en) * 2004-11-22 2011-05-03 Dharmacon, Inc. Apparatus and system having dry gene silencing compositions
US7923207B2 (en) 2004-11-22 2011-04-12 Dharmacon, Inc. Apparatus and system having dry gene silencing pools
CA2596506C (en) 2005-02-09 2021-04-06 Avi Biopharma, Inc. Antisense composition and method for treating muscle atrophy
JP2008544742A (ja) 2005-02-25 2008-12-11 アイシス ファーマシューティカルズ， インコーポレーテッド ＩＬ４Ｒ−αに対する組成物およびその使用
CA2603206A1 (en) 2005-04-08 2006-10-19 Isis Pharmaceuticals, Inc. Compositions and their uses directed to acetyl-coa carboxylases
US20060258610A1 (en) 2005-05-12 2006-11-16 Isis Pharmaceuticals, Inc. Modulation of STAT 6 expression for the treatment of airway hyperresponsiveness
US20090221671A1 (en) 2005-05-24 2009-09-03 Sanjay Pandey Modulation of lmw-ptpase expression
US7897583B2 (en) 2005-05-24 2011-03-01 Isis Pharmaceuticals, Inc. Compositions and their uses directed to PTPRU
PL3308788T3 (pl) 2005-06-23 2019-05-31 Biogen Ma Inc Kompozycje i sposoby modulacji splicingu smn2
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
US8076303B2 (en) 2005-12-13 2011-12-13 Spring Bank Pharmaceuticals, Inc. Nucleotide and oligonucleotide prodrugs
EP2428227B1 (de) 2006-01-26 2016-06-22 Ionis Pharmaceuticals, Inc. Zusammensetzung und deren Verwendungen in Bezug auf Huntingtin
EP2275543A3 (de) 2006-04-12 2011-03-09 Isis Pharmaceuticals, Inc. Zusammensetzungen und deren Verwendungen in Bezug auf Hepcidin
MX2008014005A (es) * 2006-05-03 2009-01-27 Baltic Technology Dev Ltd Agentes antisentido que combinan un oligonucleotido modificado con base fuertemente unida y nucleasa artificial.
AU2007257094B2 (en) 2006-05-05 2012-10-25 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of SGLT2
EP2505650A1 (de) 2006-05-05 2012-10-03 Isis Pharmaceuticals, Inc. Verbindungen und Verfahren zur Modulation der Expression von PCSK9
EP2023936A4 (de) 2006-05-05 2010-11-24 Isis Pharmaceuticals Inc Zusammensetzungen und ihre verwendungen in bezug auf ptpr-alpha
ES2911034T3 (es) 2006-08-08 2022-05-17 Univ Bonn Rheinische Friedrich Wilhelms Estructura y uso de oligonucleótidos 5' fosfato
JP5352462B2 (ja) * 2006-09-22 2013-11-27 ダーマコン， インコーポレイテッド 二本鎖オリゴヌクレオチド複合体、ｒｎａ干渉による遺伝子サイレンシング方法、および医薬品組成物
KR20090089854A (ko) 2006-10-12 2009-08-24 수퍼젠, 인크. Ｄｎａ 메틸화 조절을 위한 퀴놀린 유도체
DK2092065T4 (da) 2006-10-18 2019-10-21 Ionis Pharmaceuticals Inc Antisense-forbindelser
US8048998B2 (en) 2007-01-19 2011-11-01 Exiqon A/S Mediated cellular delivery of LNA oligonucleotides
ES2559313T3 (es) 2007-06-19 2016-02-11 Stratos Genomics Inc. Secuenciación de ácidos nucleicos de alto rendimiento por expansión
US7951785B2 (en) * 2007-09-21 2011-05-31 California Institute Of Technology NFIA in glial fate determination, glioma therapy and astrocytoma treatment
EP2217705A2 (de) * 2007-11-05 2010-08-18 Baltic Technology Development, Ltd. Verwendung von oligonukleotiden mit modifizierten basen bei der hybridisierung von nukleinsäuren
US7845686B2 (en) * 2007-12-17 2010-12-07 S & B Technical Products, Inc. Restrained pipe joining system for plastic pipe
US8188060B2 (en) 2008-02-11 2012-05-29 Dharmacon, Inc. Duplex oligonucleotides with enhanced functionality in gene regulation
WO2009102427A2 (en) * 2008-02-11 2009-08-20 Rxi Pharmaceuticals Corp. Modified rnai polynucleotides and uses thereof
WO2009146123A2 (en) 2008-04-03 2009-12-03 Spring Bank Compositions and methods for treating viral infections
US9738680B2 (en) 2008-05-21 2017-08-22 Rheinische Friedrich-Wilhelms-Universität Bonn 5′ triphosphate oligonucleotide with blunt end and uses thereof
WO2009143391A2 (en) * 2008-05-22 2009-11-26 Isis Pharmaceuticals, Inc Methods for modulation expression of creb
US8541388B2 (en) 2008-05-22 2013-09-24 Isis Pharmaceuticals, Inc. Methods for modulating expression of RBP4
EP2310507A4 (de) 2008-07-08 2013-03-20 David Gladstone Inst Verfahren und zusammensetzungen zur angiogenesemodulierung
WO2010008582A2 (en) 2008-07-18 2010-01-21 Rxi Pharmaceuticals Corporation Phagocytic cell drug delivery system
JP2011529686A (ja) 2008-07-29 2011-12-15 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム ポリグルタミンタンパク質発現の選択的阻害
EP2331141B1 (de) 2008-08-25 2016-01-06 Excaliard Pharmaceuticals, Inc. Gegen den bindegewebe-wachstumsfaktor gerichtete antisense-oligonukleotide und verwendungen davon
EP2949752B1 (de) 2008-09-22 2017-12-20 RXi Pharmaceuticals Corporation Selbstfreisetzende rnai-verbindungen von reduzierter grösse
EP3587434A1 (de) 2008-09-23 2020-01-01 Alnylam Pharmaceuticals Inc. Chemische modifikationen von monomeren und oligonukleotiden mit click komponenten um liganden zu konjugieren
WO2010059226A2 (en) 2008-11-19 2010-05-27 Rxi Pharmaceuticals Corporation Inhibition of map4k4 through rnai
CA2747999A1 (en) * 2008-12-23 2010-07-01 Girindus America, Inc. Sulfurizing reagents and their use for oligonucleotides synthesis
US9745574B2 (en) 2009-02-04 2017-08-29 Rxi Pharmaceuticals Corporation RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
US20120088814A1 (en) 2009-03-31 2012-04-12 Isis Pharmaceuticals, Inc. Methods of modulating an immune response to a viral infection
CA2773886C (en) 2009-09-11 2018-01-09 Isis Pharmaceuticals, Inc. Modulation of huntingtin expression
WO2011100131A2 (en) 2010-01-28 2011-08-18 Alnylam Pharmacuticals, Inc. Monomers and oligonucleotides comprising cycloaddition adduct(s)
WO2011094580A2 (en) 2010-01-28 2011-08-04 Alnylam Pharmaceuticals, Inc. Chelated copper for use in the preparation of conjugated oligonucleotides
RU2615143C2 (ru) 2010-03-24 2017-04-04 Адвирна Самодоставляющие PHKi соединения уменьшенного размера
CN110042099A (zh) 2010-03-24 2019-07-23 菲奥医药公司 皮肤与纤维化症候中的rna干扰
CN106074591B (zh) 2010-03-24 2020-01-14 菲奥医药公司 眼部症候中的rna干扰
BR112013019803A2 (pt) 2011-02-02 2019-06-11 Excaliard Pharmaceuticals Inc método de tratar quelóides ou cicatrizes hipertróficas usando os compostos anti-sentido objetivando fator de desenvolvimento de tecido conjuntivo (ctgf)
EP3067421B1 (de) 2011-02-08 2018-10-10 Ionis Pharmaceuticals, Inc. Oligomere verbindungen mit bicyclischen nukleotiden und verwendungen davon
WO2012109495A1 (en) 2011-02-09 2012-08-16 Metabolic Solutions Development Company, Llc Cellular targets of thiazolidinediones
EP2508530A1 (de) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Reinigung von triphosphorylierten Oligonucleotiden mit Einfang-Tags
WO2013022966A1 (en) 2011-08-11 2013-02-14 Isis Pharmaceuticals, Inc. Linkage modified gapped oligomeric compounds and uses thereof
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
EP3336189A1 (de) 2012-04-20 2018-06-20 Ionis Pharmaceuticals, Inc. Oligomere verbindungen mit bicyclischen nukleotiden und verwendungen davon
EP2712870A1 (de) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Neuartige RIG-I-Liganden und Herstellungsverfahren dafür
US9695418B2 (en) 2012-10-11 2017-07-04 Ionis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleosides and uses thereof
WO2014092572A1 (en) 2012-12-12 2014-06-19 Universiteit Leiden Improved methods for cancer treatment with a genotoxic agent
AU2014280847B2 (en) 2013-06-13 2019-07-04 Antisense Therapeutics Ltd Combination therapy
US20150197534A1 (en) 2013-09-05 2015-07-16 Sarepta Therapeutics, Inc. Antisense-induced exon2 inclusion in acid alpha-glucosidase
US10036020B2 (en) 2013-09-19 2018-07-31 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Compositions and methods for inhibiting JC virus (JCV)
CN106061488B (zh) 2013-12-02 2021-04-09 菲奥医药公司 癌症的免疫治疗
US11279934B2 (en) 2014-04-28 2022-03-22 Phio Pharmaceuticals Corp. Methods for treating cancer using nucleic acids targeting MDM2 or MYCN
EP4039807A1 (de) 2014-06-10 2022-08-10 Erasmus University Rotterdam Medical Center Zur behandlung der pompe-krankheit nützliche antisense-oligonukleotide
WO2016024205A1 (en) 2014-08-15 2016-02-18 Pfizer Inc. Oligomers targeting hexanucleotide repeat expansion in human c9orf72 gene
WO2016033424A1 (en) 2014-08-29 2016-03-03 Genzyme Corporation Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
US10900039B2 (en) 2014-09-05 2021-01-26 Phio Pharmaceuticals Corp. Methods for treating aging and skin disorders using nucleic acids targeting Tyr or MMP1
MA41795A (fr) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc Exclusion d'un exon induite par des composés antisens dans la myostatine
JP6873052B2 (ja) 2015-06-01 2021-05-19 サレプタ セラピューティクス，インコーポレイテッド Ｖｉｉ型コラーゲンにおけるアンチセンス誘導エクソン排除
RU2723590C2 (ru) 2015-07-02 2020-06-16 Оцука Фармасьютикал Ко., Лтд. Лиофилизированные фармацевтические композиции
WO2017007825A1 (en) 2015-07-06 2017-01-12 Rxi Pharmaceuticals Corporation Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
EP3862005A1 (de) 2015-07-06 2021-08-11 Phio Pharmaceuticals Corp. Gegen superoxid-dismutase 1 (sod1) gerichtete nukleinsäuremoleküle
EP3858993A1 (de) 2015-10-09 2021-08-04 Sarepta Therapeutics, Inc. Zusammensetzungen und verfahren zur behandlung von duchenne-muskeldystrophie und damit assoziierten erkrankungen
EP3365446A4 (de) 2015-10-19 2019-06-26 Phio Pharmaceuticals Corp. Gegen lange nichtcodierende rna gerichtete kleine selbstfreisetzende nukleinsäureverbindungen
WO2017075670A1 (en) 2015-11-05 2017-05-11 Children's Hospital Los Angeles "mobilizing leukemia cells"
CA3007152A1 (en) 2015-12-07 2017-06-15 Erasmus University Medical Center Rotterdam Enzymatic replacement therapy and antisense therapy for pompe disease
US11060089B2 (en) 2016-04-18 2021-07-13 Sarepta Therapeutics, Inc. Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene
NL2017294B1 (en) 2016-08-05 2018-02-14 Univ Erasmus Med Ct Rotterdam Natural cryptic exon removal by pairs of antisense oligonucleotides.
NL2017295B1 (en) 2016-08-05 2018-02-14 Univ Erasmus Med Ct Rotterdam Antisense oligomeric compound for Pompe disease
JP2019532027A (ja) 2016-08-17 2019-11-07 ソルスティス バイオロジクス，リミティッド ポリヌクレオチド構築物
EP3645546A4 (de) 2017-06-30 2021-12-01 Solstice Biologics, Ltd. Chirale phosphoramidithilfsmittel und verfahren zu ihrer verwendung
KR20200035438A (ko) 2017-08-03 2020-04-03 오쓰까 세이야꾸 가부시키가이샤 약물 화합물 및 이의 정제 방법
EP3697910A4 (de) 2017-10-18 2021-07-14 Sarepta Therapeutics, Inc. Antisense-oligomer-verbindungen
WO2019204743A1 (en) 2018-04-19 2019-10-24 Checkmate Pharmaceuticals, Inc. Synthetic rig-i-like receptor agonists
US20220267778A1 (en) 2019-07-30 2022-08-25 Shionogi & Co., Ltd. Nucleic acid drug targeting murf1
EP4048795A1 (de) 2019-10-23 2022-08-31 Checkmate Pharmaceuticals, Inc. Synthetische rig-i-ähnliche rezeptoragonisten

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6603690A (en) * 1989-10-05 1991-04-28 University Patents Inc. Nucleoside and polynucleotide thiophosphoramidite and phosphorodithioate compounds and processes
EP0463712A3 (en) * 1990-06-27 1992-04-08 University Patents, Inc. Polynucleotide phosphorodithioates as therapeutic agents for retroviral infections
DE4216134A1 (de) * 1991-06-20 1992-12-24 Europ Lab Molekularbiolog Synthetische katalytische oligonukleotidstrukturen
US5210264A (en) * 1992-01-10 1993-05-11 Isis Pharmaceuticals, Inc. S-(2,4-dichlorobenzyl)-β-cyanoethyl phosphorothioate diester

Also Published As

Publication number Publication date
EP0698034A1 (de) 1996-02-28
DE69404835D1 (de) 1997-09-11
EP0698034B1 (de) 1997-08-06
FR2705099A1 (fr) 1994-11-18
US5770713A (en) 1998-06-23
FR2705099B1 (fr) 1995-08-04
CA2162684A1 (en) 1994-11-24
DE69404835T2 (de) 1998-03-12
WO1994026764A1 (fr) 1994-11-24

Similar Documents

Publication Publication Date Title
ATE156488T1 (de) Triesters von phosphorothioaten oligonukleotiden und verfahren zur herstellung
ES2083299T3 (es) Metodos para secuenciacion de oligonucleotidos sinteticos que contienen enlaces internucleotidicos distintos a fosfodiester.
DE69305751D1 (de) Verfahren und geraet zur kunstlichen hautbraunung
ATE428780T1 (de) Verfahren zur zubereitung von antisense oligonukleotiden
DE69310375D1 (de) Vorrichtung und verfahren zur selbstbraünerung
DE59408289D1 (de) Beschichteter körper, verfahren zu dessen herstellung sowie dessen verwendung
DE69637593D1 (de) Arteriovenöse und venöse transplantatbehandlungen: methoden und zusammensetzungen
FI971974A (fi) Tienopyridiini- tai tienopyrimidiinijohdannaiset ja niiden käyttö
IL143748A0 (en) Substituted aryl or heteroarylamides having retinoid-like biological activity
ES2193144T3 (es) Compuestos de dna que comprenden secuencias que codifican manuronano c-5-epimerasa.
DE59410052D1 (de) Verwendung von nona- und dekapeptiden zur herstellung eines arzneimittels zur bekämpfung von aids
DE69508192D1 (de) Wasserlösliches nimesulid-salz, sowie dessen verwendung zur behandlung von entzündungen
ATE312174T1 (de) Antisense-oligonucleotide gegen hsv-1 sowie deren herstellung
SE9501808D0 (sv) New process
AP2000001937A0 (en) Method for identifying chemical active agents and active agents for inhibiting the 1-desoxy-d-xylulose-5-phosphate biosynthetic pathway.
DE59607683D1 (de) Neue borneolderivate, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung
ATE231486T1 (de) Optisch aktive 2-amino-tetraline, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen die diese enthalten und die nützlich sind zur vorbeugung und behandlung von septischem schock
SE9503844D0 (sv) Plugg för skallbenet
ATE244760T1 (de) Wachtumsfaktor aus der harp-reihe, verfahren zu ihrer herstellung und verwendungen davon
BG101983A (en) Substituted phenylamidines, medicamentous forms containing them and mehtod for their preparation
DE69418723D1 (de) Verfahren zur herstellung von 1,1,2,3,3-pentafluorpropan
CO5261508A1 (es) Compuestos bi-basicos como inhibidores de triptasa, procedimiento para su preparacion y su utilizacion como medicamentos
DE59608559D1 (de) Verfahren zur herstellung von feinverteiltes metallisches kobalt enthaltendem kobalt(ii)-oxid
HU9303318D0 (en) New 2-saccharinyl-methyl-phosphates, and phosphinates, their use as proteolytic enzime inhibitors, process for producing them, and preparations containing them
ATE161682T1 (de) Zusammensetzung zur behandlung von pflanzenmaterial